✨
AI Summary
- FDA staff cuts' potential impact on biopharma M&A discussed.
- Attorneys and Naya Therapeutics CEO share insights.
- Analysis of regulatory changes affecting deal activity.
Guests on This Episode
AM
Alan Minsk
1 podcast appearance
AG
Andrew Goodman
1 podcast appearance
DT
Daniel Teper
1 podcast appearance